Canada markets open in 1 hour 25 minutes
  • S&P/TSX

    20,762.03
    +297.43 (+1.45%)
     
  • S&P 500

    4,577.10
    +64.06 (+1.42%)
     
  • DOW

    34,639.79
    +617.75 (+1.82%)
     
  • CAD/USD

    0.7801
    -0.0007 (-0.09%)
     
  • CRUDE OIL

    68.40
    +1.90 (+2.86%)
     
  • BTC-CAD

    72,910.84
    -25.74 (-0.04%)
     
  • CMC Crypto 200

    1,453.05
    +14.16 (+0.98%)
     
  • GOLD FUTURES

    1,771.70
    +11.00 (+0.62%)
     
  • RUSSELL 2000

    2,206.33
    +58.91 (+2.74%)
     
  • 10-Yr Bond

    1.4480
    0.0000 (0.00%)
     
  • NASDAQ futures

    16,023.00
    +34.50 (+0.22%)
     
  • VOLATILITY

    27.24
    -3.88 (-12.47%)
     
  • FTSE

    7,160.43
    +31.22 (+0.44%)
     
  • NIKKEI 225

    28,029.57
    +276.20 (+1.00%)
     
  • CAD/EUR

    0.6906
    +0.0001 (+0.01%)
     

Stocks in play: Oncolytics Biotech Inc.

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Announced that its partner Adlai Nortye has initiated dosing in a bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer. Results from the bridging trial are expected to allow Adlai Nortye to include data from Oncolytics' North American metastatic breast cancer trials in a future submission to Chinese regulators. The first of Oncolytics' randomized phase 2 trials, IND-213, showed that treatment with pelareorep and paclitaxel led to a statistically significant increase in overall survival compared to treatment with paclitaxel alone. Oncolytics' second randomized phase 2 trial, BRACELET-1, is ongoing and evaluates pelareorep-paclitaxel combination therapy both with and without a checkpoint inhibitor. Oncolytics Biotech Inc. shares T.ONC are trading unchanged at $2.65.

Read:

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting